Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study

Shoab, SS; Porter, JC; Scurr, J. H.; Coleridge-Smith, P.

doi:10.1067/mva.2000.102724

Cited by 50 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that pharmacological intervention to reduce white blood cell activation might be useful in treating skin changes of CVI. One such method might be to use drugs that decrease leukocyte adhesion to endothelium (36). Micronized purified flavonoid fraction (MPFF), by inhibiting leukocyte adhesion and migration through endothelium, fights the microcirculation damaging processes (36).…”

Section: Possibilities For Therapeutic Targeting Of the Microcirculationmentioning

confidence: 99%

“…One such method might be to use drugs that decrease leukocyte adhesion to endothelium (36). Micronized purified flavonoid fraction (MPFF), by inhibiting leukocyte adhesion and migration through endothelium, fights the microcirculation damaging processes (36). Clinically, studies have shown that an improved healing rate of ulcerations is seen when patients treated with pentoxifylline are compared to those treated with a placebo (12).…”

Section: Possibilities For Therapeutic Targeting Of the Microcirculationmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Management of Chronic Venous Insufficiency: Microcirculation as a Target

Bergan

Schmid‐Schönbein

2000

Microcirculation

View full text Add to dashboard Cite

Chronic venous insufficiency, in its most severe manifestations as well as in its mild form, is linked to venous valve failure, weakness of the venous wall, and leukocyte-endothelial interactions all of which lead to cutaneous and subcutaneous tissue changes. These in turn are related to venous hypertension-induced leukocyte activation, which may provide a target for pharmacotherapeutic intervention. Currently, surgical attack is focused on correction of the sources of venous hypertension, but it is felt that this provides a crude method that hopefully will be replaced by more precise pharmacological interventions. Microcirculation (2000) 7, S23-S28.Therapeutic management of chronic venous insufficiency JJ Bergan and GW Schmid-Schö nbein S27Therapeutic management of chronic venous insufficiency JJ Bergan and GW Schmid-Schö nbein S28

show abstract

Section: Possibilities For Therapeutic Targeting Of the Microcirculationmentioning

confidence: 99%

Section: Possibilities For Therapeutic Targeting Of the Microcirculationmentioning

confidence: 99%

Therapeutic Management of Chronic Venous Insufficiency: Microcirculation as a Target

Bergan

Schmid‐Schönbein

2000

Microcirculation

View full text Add to dashboard Cite

show abstract

“…Daflon 500 mg twice daily for 60 days has been shown to reduce markers of inflammation at the microcirculatory level in a nonblinded study of 20 patients with CVD [66][67][68].…”

Section: Leukocyte Activation and Adhesionmentioning

confidence: 99%

“…During CVD, microcirculatory changes result in ischemic areas [68]. In two studies of patients with mild to moderate CVD, Daflon 500 mg significantly improved venous oximetry measurements from baseline [73,74].…”

Section: Hemorheological Changesmentioning

confidence: 99%

Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease

Pascarella¹

2007

CPD

View full text Add to dashboard Cite

Primary chronic venous disease (CVD) is a common condition that can cause significant morbidity for sufferers and considerable burden on health care systems. Prolonged venous hypertension in conjunction with valvular incompetence and venous reflux is responsible for the diverse clinical manifestations of CVD and links all theories regarding CVD pathogenesis.Recent data suggest that valve damage may be acquired rather than congenital, and caused by inflammatory factors, notably leukocyte activation triggered by venous hypertension. Valve incompetence leads to reflux, reinforcing venous pressure elevation and initiating a vicious circle of disease progression. Loss of venous tone and lymphatic overload also play a role. Valve failure in superficial and perforating veins leads to elevated pressure in the veins and venules of the skin and subcutaneous tissue, resulting in skin hyperpigmentation, induration and ultimately ulceration.The inflammatory cascade may be ameliorated by pharmacologic intervention to decrease leukocyte activation and leukocyte endothelial interactions at both macro-and microcirculatory levels. Daflon 500 mg (micronized purified flavonoid fraction) offers great potential for achieving this with demonstrated efficacy in reducing inflammation and thus providing tissue protection at all stages of the disease. Experiments in animal and human models of CVD have shown that Daflon 500 mg modulates leukocyte rolling and adhesion and prevents endothelial damage in both veins and capillaries. Such treatment is useful for first-line management of edema as well as associated symptoms of CVD. A recent meta-analysis has confirmed that venous leg ulcer healing is accelerated by adding Daflon 500 mg to conventional treatment.

show abstract

“…The effects of MPFF on systemic inflammatory mediators have been studied in a recent pilot study (31,32). Twenty patients with chronic venous disease (CEAP clinical stage 2-4) were treated for 60 days with MPFF 500 mg twice daily, taken orally.…”

Section: Flavonoid Treatment In CVI Pd Coleridge Smith S37mentioning

confidence: 99%

Micronized Purified Flavonoid Fraction and the Treatment of Chronic Venous Insufficiency: Microcirculatory Mechanisms

Smith¹

2000

Microcirculation

View full text Add to dashboard Cite

The standard treatments for venous diseases of the lower limb include compression bandaging and stockings as well as surgical removal of varicose veins. There is a number of conditions in which these conventional treatments are ineffective, particularly in the management of leg ulceration. Drug treatments for healing venous leg ulcers have yet to be developed to the stage of good clinical efficacy, but may assist in the management of patients. Flavonoid drugs have been widely used in the management of the symptoms of venous disease for many years and have recently been studied in some detail to assess their effects on the microcirculation. Work in animal models of ischemia/reperfusion (I/R) show that micronized purified flavonoid fraction (MPFF) modulates leukocyte adhesion and prevents endothelial damage. Similar biochemical effects have been observed in patients with venous disease and may explain the efficacy of this drug in the management of edema and other symptoms of venous disease. There is some evidence that MPFF promotes venous leg ulcer healing.

show abstract

Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study

Cited by 50 publications

References 18 publications

Therapeutic Management of Chronic Venous Insufficiency: Microcirculation as a Target

Therapeutic Management of Chronic Venous Insufficiency: Microcirculation as a Target

Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease

Micronized Purified Flavonoid Fraction and the Treatment of Chronic Venous Insufficiency: Microcirculatory Mechanisms

Contact Info

Product

Resources

About